#pharmaceutical

Les entreprises de biopharmaceutique restructurent les accords de licence internationaux pour réduire leur exposition aux règles de fixation des prix du statut de nation la plus favorisée, qui lient les prix des médicaments aux États-Unis aux prix les plus bas payés dans d'autres pays.

Ugur Sahin and Ozlem Tureci will exit BioNTech by year-end to start a company focused on next-generation mRNA innovations.

Pharmaceutical giant GSK has agreed to buy 35Pharma, a biotech focused on pulmonary hypertension, for $950 million. The deal expands GSK's respiratory and cardiovascular portfolio with a pipeline targeting a disease that currently has limited treatment options.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.